Accessibility Menu
Alaunos Therapeutics logo

Alaunos Therapeutics

(NASDAQ) TCRT

Current Price$2.05
Market Cap$4.86M
Since IPO (2005)-100%
5 Year-100%
1 Year-36%
1 Month-23%

Alaunos Therapeutics Financials at a Glance

Market Cap

$4.86M

Revenue (TTM)

$3.00K

Net Income (TTM)

-$4.11M

EPS (TTM)

-$2.17

P/E Ratio

-0.92

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$2.05

Volume

4,343.723

Open

$1.99

Previous Close

$1.99

Daily Range

$1.98 - $2.01

52-Week Range

$1.67 - $6.20

Estimated Earnings Date

Aug 18, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alaunos Therapeutics

Industry

Biotechnology

Employees

1

CEO

Holger Weis, CPA

Headquarters

Houston, TX 77054, US

TCRT Financials

Key Financial Metrics (TTM)

Gross Margin

-63%

Operating Margin

-1382%

Net Income Margin

-1370%

Return on Equity

-350%

Return on Capital

-3%

Return on Assets

-2%

Earnings Yield

-1.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.86M

Shares Outstanding

2.44M

Volume

4.34K

Avg. Volume

17.09K

Financials (TTM)

Gross Profit

$5.00K

Operating Income

-$4.23M

EBITDA

-$4.23M

Operating Cash Flow

-$2.87M

Capital Expenditure

-$98.00K

Free Cash Flow

-$2.97M

Cash & ST Invst.

$1.39M

Total Debt

$0.00

Alaunos Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$8.00K

-500.0%

Gross Margin

0.00%

N/A

Market Cap

$4.86M

N/A

Market Cap/Employee

$4.86M

N/A

Employees

1

N/A

Net Income

-$1.01M

+6.2%

EBITDA

-$1.01M

+5.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$354.00K

+11.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-2.18%

N/A

Return on Invested Capital

-3.22%

N/A

Free Cash Flow

-$1.03M

-33.5%

Operating Cash Flow

-$1.03M

-33.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADXNAddex Therapeutics Ltd
$7.27+16.69%
XTLBXTL Biopharmaceuticals Ltd.
$2.24-3.45%
KTTAPasithea Therapeutics Corp.
$0.58-0.76%
RADXRadiopharm Theranostics Limited
$4.26+0.24%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.52+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.30-0.06%
KEELKeel Infrastructure
$5.45+0.00%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.10+0.04%

Questions About TCRT

What is the current price of Alaunos Therapeutics?

Alaunos Therapeutics is trading at $2.00 per share.

What is the 52-week range for Alaunos Therapeutics?

Over the past 52 weeks, Alaunos Therapeutics has traded between $1.67 and $6.20.

How much debt does Alaunos Therapeutics have?

As of the most recent reporting period, Alaunos Therapeutics reported total debt of $0.00.

How much cash does Alaunos Therapeutics have on hand?

Alaunos Therapeutics reported $354.00K in cash and cash equivalents in its most recent financial results.

What is Alaunos Therapeutics’s dividend yield?

Alaunos Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.